FY2026 Earnings Estimate for Immunic Issued By HC Wainwright

Immunic logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 EPS estimate for Immunic to a loss of $3.24 per share from a loss of $3.18, while maintaining a Buy rating and a $22 price target.
  • Immunic reported a quarterly loss of $0.99 per share, worse than analysts’ expected loss of $0.79.
  • Analyst sentiment is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus rating and an average price target of $35.43.
  • MarketBeat previews the top five stocks to own by December 1st.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($3.24) for the year, down from their previous forecast of ($3.18). HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Immunic's current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Immunic's Q4 2026 earnings at ($0.56) EPS, FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.60) EPS.

Several other analysts also recently commented on IMUX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunic in a research report on Wednesday, August 26th. Wedbush reiterated an "outperform" rating and issued a $45.00 price objective on shares of Immunic in a research note on Thursday, September 10th. Zacks Research downgraded shares of Immunic from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 10th. Cantor Fitzgerald began coverage on shares of Immunic in a research note on Friday, October 23rd. They set an "overweight" rating on the stock. Finally, Roth Capital reissued a "buy" rating on shares of Immunic in a research note on Tuesday, September 1st. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Immunic currently has an average rating of "Moderate Buy" and an average target price of $35.43.

Read Our Latest Analysis on IMUX

Immunic Price Performance

Shares of IMUX opened at $7.33 on Wednesday. Immunic has a 52-week low of $5.06 and a 52-week high of $17.43. The business's 50 day moving average price is $8.47 and its two-hundred day moving average price is $11.53.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.20).

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMUX. Avidity Partners Management LP boosted its holdings in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock worth $7,436,000 after acquiring an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Immunic in the first quarter valued at approximately $1,020,000. Braidwell LP bought a new stake in shares of Immunic during the second quarter valued at approximately $9,914,000. Aberdeen Group plc increased its holdings in shares of Immunic by 32.3% during the third quarter. Aberdeen Group plc now owns 1,090,427 shares of the company's stock valued at $10,141,000 after acquiring an additional 266,034 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Immunic by 242.8% during the third quarter. Marshall Wace LLP now owns 359,319 shares of the company's stock valued at $3,342,000 after acquiring an additional 254,503 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

Top Immunic Stories

Investors following IMUX have been watching these stories:

  • Positive Sentiment: HC Wainwright, which maintains a “Buy” rating and $22 price target, raised its 2027 EPS estimate to a loss of $2.27 per share from $2.47 and its fourth-quarter 2026 estimate to a loss of $0.56 from $0.68.
  • Negative Sentiment: HC Wainwright lowered its estimates for 2026, 2028, 2029 and 2030, while Brookline Capital Markets also reduced its 2026 and fourth-quarter 2026 forecasts. The downward revisions point to expectations of greater losses than previously projected.
  • Negative Sentiment: Wall Street Zen cut Immunic to “Strong Sell,” adding a bearish rating signal. Immunic NASDAQ: IMUX Cut to “Strong Sell” at Wall Street Zen

About Immunic

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company's research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Featured Articles

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunic Right Now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines